Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer

Completed

• Conditions: Cancer of the Uterine Cervix

• Registration Number: NCT00193934
• Lead Sponsor: Trans Tasman Radiation Oncology Group

Brief Summary

The researchers propose that it may be corpus invasion, rather than tumour volume per se, which is one of the important determinants of ultimate outcome in cervix cancer. The aim of the proposed prospective, multicentre study, is to confirm the results of our retrospective studies, specifically that corpus invasion or tumour volume or both contribute important prognostic information over and above that provided by the currently used International Federation of Gynecology and Obstetrics (FIGO) staging system. A successful outcome would have important implications for the staging, and management as well as the biologic understanding of the behaviour of cervical cancer.

Detailed Description

This will be a prospective, multicentre, prognostic factor, follow-up study. The study is designed to be as simple as possible: newly diagnosed cervical cancer patients will have key prognostic variables collected at baseline. The treatment received will be documented at the end of treatment and patients will then be followed for first relapse and survival.

Registration of a patient on this study can be undertaken after EUA, biopsy confirmed diagnosis, anatomic staging diagram and MRI have been done and before any treatment has commenced.

Treatment must be curative in intent (termed radical therapy) but otherwise can be at the discretion of the investigator. Radical hysterectomy alone, hysterectomy followed by adjuvant radiotherapy, radical chemo-radiotherapy or radical radiotherapy will be allowed. Details of the planned and given treatment regimen will be recorded.

All patients will have the following trial data documented at the time of registration:

* Age

* ECOG performance status

* smoking status

* date of histological diagnosis

* histologic type and features

* presenting haemoglobin

* standard FIGO staging

* maximum clinical tumour diameter measured at EUA

* detailed staging diagram drawn at EUA

* nodal status (by surgical pathology or CT or MRI or both and PET if available)

* date of MRI

* MRI tumour diameters

* presence or absence of corpus invasion on MRI

* planned treatment details

All patients will be assessed pre-treatment, immediately following treatment and will be followed up for local control and survival at yearly intervals from the date of registration.

It is intended to collect follow up information on all patients until one year after the final patient is registered on study.

Study Timeline

• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-19
• Study Start: 2006-01
• Primary Completion: 2014-05
• Study Completion: 2014-05-15
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-10
• Last Update Posted: 2017-07-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 109

Inclusion Criteria

1. Newly diagnosed, biopsy proven carcinoma of the uterine cervix.
2. Squamous cell, adenocarcinoma, adenosquamous or large cell carcinoma histology.
3. FIGO Stage Ib -IVa.
4. Maximum clinical tumour diameter recorded.
5. MRI done within 30 days prior to registration.
6. Intention to treat radically
7. Treatment not yet started.
8. Written informed consent.
9. Available for follow-up.

Exclusion Criteria

1. Lymphoma, small cell carcinoma and melanoma histology.
2. Previous hysterectomy
3. Pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assess the prognostic significance, with respect to overall survival, of the factors, FIGO stage. Overall survival is defined as the date of registration to date of death from any cause.	End of study

Trial Locations

Locations (16)

Royal Adelaide Hospital; 🇦🇺 Adelaide, South Australia, Australia

Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States

Liverpool Hospital; 🇦🇺 Liverpool, New South Wales, Australia

Royal North Shore Hospital; 🇦🇺 Sydney, New South Wales, Australia

Westmead Hospital; 🇦🇺 Wentworthville, New South Wales, Australia

Royal Brisbane Hospital; 🇦🇺 Herston, Queensland, Australia

North Queensland Oncology Service; 🇦🇺 Townsville, Queensland, Australia

Premion - Tugun; 🇦🇺 Tugun, Queensland, Australia

Tata Memorial Hospital; 🇮🇳 Mumbai, India

Meenakshi Mission Hospital; 🇮🇳 Tamil Nadu, India

Dunedin Hospital; 🇳🇿 Dunedin, New Zealand

Peter MacCallum Cancer Centre; 🇦🇺 Melbourne, Victoria, Australia

National University Hospital; 🇸🇬 Singapore, Singapore

Calvary Mater Newcastle; 🇦🇺 Newcastle, New South Wales, Australia

Auckland Hospital; 🇳🇿 Auckland, New Zealand

Christchurch Hospital; 🇳🇿 Christchurch, New Zealand